Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma

Clinical Cancer Research

Volumn 16, Issue 15, 2010, Pages 3860-3874

  Parris, Toshima Z ^a   Danielsson, Anna ^a   Nemes, Szilárd ^a   Kovács, Anikó ^a   Delle, Ulla ^a   Fallenius, Ghita ^a   Möllerström, Elin ^a   Karlsson, Per ^a   Helou, Khalil ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; ONCOPROTEIN; PROTEIN AZGP1; PROTEIN CBX2; PROTEIN DNALI1; PROTEIN LOC389033; PROTEIN NME5; PROTEIN PIP; PROTEIN SCUBE2; PROTEIN SERPINA11; PROTEIN STC2; PROTEIN SUSD3; PROTEIN UBE2C; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DOWN REGULATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE MAPPING; GENOMICS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR GROWTH;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; CELL SEPARATION; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DIPLOIDY; FEMALE; FLOW CYTOMETRY; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77955101694     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0889     Document Type: Article

References (50)

1. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41.
2. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177-83.
3. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet 2003;34:369-76.
4. Tsuda H. Gene and chromosomal alterations in sporadic breast cancer: correlation with histopathological features and implications for genesis and progression. Breast Cancer 2009;16:186-201.
5. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-11.
6. Hyman E, Kauraniemi P, Hautaniemi S, et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002;62:6240-5.
7. Reyal F, Stransky N, Bernard-Pierrot I, et al. Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes-a study of 130 invasive ductal breast carcinomas. Cancer Res 2005;65:1376-83.
8. Farabegoli F, Santini D, Ceccarelli C, Taffurelli M, Marrano D, Baldini N. Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH. Cytometry 2001;46:50-6.
9. Hicks J, Krasnitz A, Lakshmi B, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006;16:1465-79.
10. Hicks J, Muthuswamy L, Krasnitz A, et al. High-resolution ROMA CGH and FISH analysis of aneuploid and diploid breast tumors. Cold Spring Harb Symp Quant Biol 2005;70:51-63.
11. Rennstam K, Baldetorp B, Kytola S, Tanner M, Isola J. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res 2001;61:1214-9. (Pubitemid 32174445)
12. Ried T, Heselmeyer-Haddad K, Blegen H, Schrock E, Auer G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer 1999;25:195-204.
13. Tanner MM, Karhu RA, Nupponen NN, et al. Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am J Pathol 1998;153:191-9.
14. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998;21:177-84.
15. Truong K, Vielh P, Guilly MN, et al. Quantitative FISH analysis on interphase nuclei may improve diagnosis of DNA diploid breast cancers. Diagn Cytopathol 2002;26:213-6.
16. Habermann JK, Doering J, Hautaniemi S, et al. The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer 2009;124:1552-64.
17. Ried T, Just KE, Holtgreve-Grez H, et al. Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res 1995;55:5415-23.
18. Leers MP, Nap M. Steroid receptor heterogeneity in relation to DNA index in breast cancer: a multiparameter flow cytometric approach on paraffin-embedded tumor samples. Breast J 2001;7:249-59.
19. Jonsson G, Staaf J, Olsson E, et al. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2007;46:543-58.
20. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 2002;3, SOFTWARE0003.
21. Moore SR, Persons DL, Sosman JA, et al. Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res 2008;14:2927-35.
22. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet 2004;36:949-51.
23. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009;15:907-13.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;57:289-300.
25. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
26. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-46.
27. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
28. Karlsson E, Delle U, Danielsson A, et al. Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer. BMC Cancer 2008;8:254.
29. Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res 2002;12:996-1006.
30. Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009;15:441-51.
31. Fridlyand J, Snijders AM, Ylstra B, et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006;6:96.
32. Haverty PM, Fridlyand J, Li L, et al. High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer 2008;47:530-42. (Pubitemid 351657188)
33. Loo LW, Grove DI, Williams EM, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004;64:8541-9.
34. Naylor TL, Greshock J, Wang Y, et al. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 2005;7:R1186-98.
35. Nessling M, Richter K, Schwaenen C, et al. Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 2005;65:439-47.
36. Knuutila S, Bjorkqvist AM, Autio K, et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998;152:1107-23.
37. Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets 2008;8:243-52.
38. Chapman EJ, Kelly G, Knowles MA. Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol Cancer Res 2008;6:1154-68.
39. Cheng CJ, Lin YC, Tsai MT, et al. SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. Cancer Res 2009;69:3634-41.
40. Cunha IW, Carvalho KC, Martins WK, et al. Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol 2010;3:23-32.
41. Fujita T, Ikeda H, Taira N, Hatoh S, Naito M, Doihara H. Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer. BMC Cancer 2009;9:87.
42. Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W, Madden JF. Zinc α-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 2001;7:846-53. (Pubitemid 32708720)
43. Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F. Prolactin inducible protein in cancer, fertility and immunoregulation: structure, function and its clinical implications. Cell Mol Life Sci 2009;66:447-59.
44. Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res 2003;63:4167-73.
45. Gruvberger S, Ringner M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-84.
46. Berlingieri MT, Pallante P, Sboner A, et al. UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer 2007;43:2729-35.
47. McAvoy S, Ganapathiraju SC, Ducharme-Smith AL, et al. Nonrandom inactivation of large common fragile site genes in different cancers. Cytogenet Genome Res 2007;118:260-9.
48. SmithDI, Zhu Y, McAvoy S, Kuhn R. Common fragile sites, extremely large genes, neural development and cancer. Cancer Lett 2006;232:48-57.
49. O'Dushlaine C, Kenny E, Heron E, et al. Molecular pathways involved in neuronal cell adhesion andmembrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. Mol Psychiatry 2010.
50. Omura N, Li CP, Li A, et al. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther 2008;7:1146-56.